Stemchymal® for the treatment of Osteoarthritic Knee
Osteoarthritis in the knee (OA Knee) begins with the gradual deterioration of cartilage. Without the protective cartilage, the bones eventually begin to rub together, causing pain, loss of mobility, and deformity. Cartilage in the knee begins to break down and ultimately the bones of the knee rub against each other as you walk. OA knee is the leading cause of disability in the elderly.
A newly published CDC study reports that the lifetime risk of symptomatic knee osteoarthritis (OA) may be nearly one in two, or 46%. The study authors also found that nearly two in three obese adults may develop painful knee osteoarthritis during their lifetime. In 2004, $14.3 billion were spent on hospital costs associated with total knee replacements in the US.(www.cdc.gov/arthritis/resources/spotlights/osteoarthritis.htm)
Steminent scientists believe that earlier, intra-articular interventions with cell therapy may prevent the progression of OA Knee and reduce, or substantially delay joint degeneration, which will require joint replacement treatments.
Steminent is conducting an autologous mesenchymal stem cells Phase I/II clinical trial for treating Osteoarthritic Knee (NCT02544802).